メニューをスキップします

国立研究開発法人 医薬基盤・健康・栄養研究所

ホーム > 生体機能分子制御プロジェクト > English > Publications

Publications

(*Corresponding author)（○：当研究室に所属する研究員が主となって行った研究成果)

2024

  1. Kim S, Matsushita Y, Katagiri T, Maseda H. Efficiency of genome editing using modified single-stranded oligodeoxyribonucleotides in human cells. Sci Rep. 2025 Mar 21;15(1):9764.
  2. Murao N, Matsuda T, Kadowaki H, Matsushita Y, Tanimoto K, Katagiri T, Nakashima K, Nishitoh H. The Derlin-1-Stat5b axis maintains homeostasis of adult hippocampal neurogenesis. EMBO Rep. 2024 Aug;25(8):3678-3706.
  3. Kobayashi D, Denda M, Hayashi J,Hidaka K, Kohmura Y, Tsunematsu T, Nishino K, Yoshikawa H, Ohkawachi K, Nigorikawa K, Yoshimaru T, Ishimaru N, Nomura W, Katagiri T, Kosako H, Otaka A. Sulfoxide-mediated Cys-Trp-selective bioconjugation that enables protein labeling and peptide heterodimerization. ChemistryEurope 2024, 2;e202400014.
  4. Harada A*, Kunii M*, Kurokawa K*, Sumi T*, Kanda S, Zhang Y, Nadanaka S, Hirosawa KM, Tokunaga K, Tojima T, Taniguchi M, Moriwaki K, Yoshimura S, Yamamoto Hino M, Goto S, Katagiri T, Kume S, Hayashi-Nishino M, Nakano M, Miyoshi E, Suzuki KGN, Kitagawa H, Nakano A. Dynamic movement of the Golgi unit and its glycosylation enzyme zones. Nat Communi, 2024 May 27;15(1):4514.
  5. ○Iijima N*. The emerging role of effector functions exerted by tissue-resident memory T cells. Oxford open immunology. Volume 5, Issue 1, 2024, iqae006, 2024 (*Corresponding author)
  6. ○Sakurai K, Morita M, Aomine Y, Matsumoto M, Moriyama T, Kasahara E, Sekiyama A, Otani M, Oshima R, Loveland K.L, Yamada M, Yoneda Y, Oka M, Hikida T, Miyamoto Y. (Corresponding author) Importin α4 deficiency induces psychiatric disorder-related behavioral deficits and neuroinflammation in mice. Translational Psychiatry, 14:426 (2024)
  7. ○Iijima N*§, Yamaguchi M, Hayashi T, Rui Y, Ohira Y, Miyamoto Y, Niino M, Okuno T, Suzuki O, Oka M, Ishii KJ*. miR-147-3p in pathogenic CD4+ T cells controls chemokine receptor expression for the development of experimental autoimmune diseases. Journal of Autoimmunity, 149, 103319 (2024) (*Corresponding author § Lead contact).
  8. ○Itoh Y, Miyamoto Y. (Co-first), Tokunaga M, Suzuki T, Takada A, Ninomiya A, Hishinuma T, Matsuda M, Yoneda Y, Oka M, Suzuki R, Matsuura Y, Okamoto T. Importin-7-dependent nuclear translocation of the Flavivirus core protein is required for infectious virus production. PLOS Pathogens, 20(8): e1012409 (2024)
  9. ○Iijima N*§, Hayashi T, Niino M, Miyamoto Y, Oka M, Ishii KJ*. Tridecylcyclohexane is a critical component of incomplete Freund’s adjuvant that triggers experimental autoimmune diseases. Eur. J. Immunol., eji.202350957 (2024)(*Corresponding author § Lead contact)
  10. Nomiya H, Sakurai K, Miyamoto Y, Oka M, Yoneda Y, Hikida T, Yamada M. 
    A Kpna1-deficient psychotropic drug-induced schizophrenia model mouse for studying gene–environment interactions. Sci. Rep. 14(1), 3376 (2024)

2023

  1. Namkaew J, Zhang J, Yamakawa N, Hamada Y, Tsugawa K, Oyadomari M, Miyake M, Katagiri T, Oyadomari S. Repositioning of mifepristone as an integrated stress response activator to potentiate cisplatin efficacy in non-small cell lung cancer. Cancer Lett. 2023 Nov 28;582:216509. 
  2. Sudo H, Tsuji BA, Sugyo, A Harada Y, Nagayama S, Katagiri T, Nakamura Y, Higashi T. Head-to-head comparison of three bifunctional chelating agents reveals DOTAGA promising for 225Ac labeling of the anti-FZD10 antibody OTSA101. Cancer Sci. 2023 Dec;114(12):4677-4690.
  3. Saito A*, Kamikawa Y, Ito T, Matsuhisa K, Asada Kitamura R, Kaneko M, Okamoto T, Yoshimaru T, Matsushita Y, Katagiri T, and Imaizumi K. p53-independent tumor suppression by cell cycle arrest via CREB/ATF transcription factor OASIS. Cell Rep. 2023 May 30;42(5):112479.
  4. Okuda K, Nakahara K, Ito A, Iijima Y, Nomura R, Kumar A, Fujikawa K, Adachi K, Shimada Y, Fujio S, Yamamoto R, Takasugi N, Onuma K, Osaki M, Okada F, Ukegawa T, Takeuchi Y, Yasui N, Yamashita A, Marusawa H, Matsushita Y, Katagiri T, Shibata T, Uchida K, Niu SY, Lang NB, Nakamura T, Zhang KYJ, Lipton SA, Uehara T.. Pivotal role 1 for S-nitrosylation of DNA methyltransferase in epigenetic regulation. Nat Communi. 2023 Feb 4;14(1):621.

2022

  1. Mori, T, Okamoto, Y, Mu A, Ide Y, Yoshimura A, Senda N, Inagaki-Kawata Y, Kawashima M, Kitao H, Tokunaga E, Miyoshi Y, Ohsumi S, Tsugawa, K, Ohta T, Katagiri T, Ohtsuru S, Koike K, Ogawa S, Toi M, Iwata H, Nakamura S, Matsuo K, Takata M*. Lack of impact of the ALDH2 rs671 variant on breast cancer development in Japanese BRCA1/2-mutation carriers. Cancer Med. 2022 Nov 7;12(6):6594-6602.
  2. Fujimori S, Ohigashi I, Abe H, Matsushita Y, Katagiri T, Taketo MM, Takahama Y, Takada S. Fine-tuning of b-catenin in thymic epithelial cells is required for postnatal T cell development. eLife. 2022 Jan 19;11: e69088.
  3. Sudo H, Tsuji AB, Sugyo A, Harada Y, Nagayama S, Katagiri T, Nakamura Y, Higashi T. Frizzled homolog 10-targeted alpha-radioimmunotherapy with 225Ac-labeled OTSA101 provides decreased tumor volume and prolonged survival in the synovial sarcoma mouse model SYO-1. Cancer Sci. 2022 Feb;113(2):721-732.

2021

  1. ○Toki S, Yoshimaru T, Matsushita Y, Aihara H, Ono M, Tsuneyama K, Sairyo K, Katagiri T*. Disruption of mitochondrial BIG3-PHB2 complex suppresses the malignant progression of osteosarcoma cells. Cancer Sci. 2021 Oct;112(10):4208-4219
  2. Sugiyama T, Murao N, Kadowaki H, Takao K, Miyakawa T, Matsushita Y, Katagiri T, Futatsugi A, Shinmyo Y, Kawasaki H, Sakai J, Shiomi K, Nakazato M, Takeda K, Mikoshiba K, Ploegh HL, Ichijo H, Nishitoh H. ERAD components Derlin-1 and Derlin-2 are essential for postnatal brain development and motor function. iScience. 2021 Jun 19;24(7):102758.

2020

  1. Ishigaki K, Akiyama M, Kanai M, Takahashi A, Kawakami E, Sugishita H, Sakaue S, Matoba N, Low SK, Okada Y, Terao C, Amariuta T, Gazal S, Kochi Y, Horikoshi M, Suzuki K, Ito K, Koyama S, Ozaki K, Niida S, Sakata Y, Sakata Y, Kohno T, Shiraishi K, Momozawa Y, Hirata M, Matsuda K, Ikeda M, Iwata N, Ikegawa S, Kou I, Tanaka T, Nakagawa H, Suzuki A, Hirota T, Tamari M, Chayama K, Miki D, Mori M, Nagayama S, Daigo Y, Miki Y, Katagiri T, Ogawa O, Obara W, Ito H, Yoshida T, Imoto I, Takahashi T, Tanikawa C, Suzuki T, Sinozaki N, Minami S, Yamaguchi H, Asai S, Takahashi Y, Yamaji K, Takahashi K, Fujioka T, Takata R, Yanai H, Masumoto A, Koretsune Y, Kutsumi H, Higashiyama M, Murayama S, Minegishi N, Suzuki K, Tanno K, Shimizu A, Yamaji T, Iwasaki M, Sawada N, Uemura H, Tanaka K, Naito M, Sasaki M, Wakai K, Tsugane S, Yamamoto M, Yamamoto K, Murakami Y, Nakamura Y, Raychaudhuri S, Inazawa J, Yamauchi T, Kadowaki T, Kubo M, Kamatani Y. Nat Genet. 2020 Jul;52(7):669-679.
  2. Fujimoto Y, Inoue, N, Morimoto K, Watanabe T, Hirota S, Imamura M, Matsushita Y, Katagiri T, Okamura H, *Miyoshi Y. Significant association between high serum CCL5 levels and better disease-free survival of patients with early breast cancer. Cancer Sci. 2020 Jan;111(1):209-218.
  3. ○ #Kimura R, #Yoshimaru T, #Matsushita Y, Matsuo T, Ono M, Park JH, Sasa M, Miyoshi Y, Nakamura Y, *Katagiri T. The GALNT6-LGALS3BP axis promotes breast cancer cell growth. Int J Oncol. 2020 Feb;56(2):581-595. (# equal contribution)

2019

  1. Ohigashi I, Tanaka Y, Kondo K, Fujimori S, Kondo H, Palin AC, Kozai M, Matsushita Y, Uda S, Kubota H, Murata S, Tanaka K, Katagiri T, Kosako H, *Takahama Y. Trans-omics impact of thymoproteasome in cortical thymic epithelial cells. Cell Rep. 2019 Nov 26;29(9):2901-2916.
  2. ○*Low SK, Ito H, Matsuo K, Tanikawa C, Matsuda K, Saito H, Sakurai-Yageta M, Nakaya N, Shimizu A, Nishizuka SS, Yamaji T, Sawada N, Iwasaki M, Tsugane S, Takezaki T, Suzuki S, Naito M, Waka K, Kamatani Y, Momozawa Y, Murakami Y, Inazawa J, Nakamura Y, Kubo M, Katagiri T, * Miki Y. Identification of the two novel breast cancer loci through large-scale genome-wide association study in the Japanese population. Sci Rep. 2019 Nov 22;9(1):17332.
  3. Inoue N, Li W, Fujimoto Y, Matsushita Y, Katagiri T, Okamura H, *Miyoshi Y. High Serum Levels of Interleukin-18 Are Associated With Worse Outcomes in Patients With Breast Cancer. Anticancer Res. 2019 Sep;39(9):5009-5018. (IF: 1.935)
  4. Chigira T, Nagatoishi S, Takeda H, Yoshimaru T, Katagiri T, *Tsumoto K. Biophysical characterization of the breast cancer-related BIG3-PHB2 interaction: Effect of non-conserved loop region of BIG3 on the structure and the interaction. Biochem Biophys Res Commun. 2019 Oct 8;518(1):183-189. (IF: 2.705)

2018

  1. *Momozawa Y, Iwasaki Y, Parsons MT, Kamatani Y, Takahashi A, Tamura C, Katagiri T, Yoshida T, Nakamura S, Sugano K, Miki Y, Hirata M, Matsuda K, Spurdle AB, *Kubo M. Germline pathogenic variants of 11 breast cancer genes in 7,051 Japanese patients and 11,241 controls. Nat Commun. 2018 Oct 4;9(1):4083.
  2. Deng B, Tarhan YE, Ueda K, Ren L, Katagiri T, Park JH, *Nakamura Y. Critical role of estrogen receptor alpha O-glycosylation by N-acetylgalactosaminyltransferase 6 (GALNT6) in its nuclear localization in breast cancer cells. Neoplasia. 2018 Oct;20(10):1038-1044.
  3. Giraudet AL, Cassier PA, Iwao-Fukukawa C, Garin G, Badel JN, Kryza D, Chabaud S, Gilles-Afchain L, Clapisson G, Desuzinges C, Sarrut D, Halty A, Italiano A, Mori M, Tsunoda T, Katagiri T, Nakamura Y, Alberti L, Cropet C, Baconnier S, Berge-Montamat S, Pérol D, Blay JY. A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients. BMC Cancer. 2018 Jun 8;18(1):646.
  4. Kato Y, Zembutsu H, Takata R, Matsuura T, Kato R, Kanehira M, Iwasaki K, Yamada N, Katagiri T, Sugai T, Fujioka T, Nakamura Y, *Obara W. A prospective study to examine the accuracies and efficacies of prediction systems for response to neoadjuvant chemotherapy for muscle invasive bladder. Oncology Letters. 2018, Nov;16(5):5775-5784.
  5. Li HK, Sugyo A, Tsuji AB, Morokoshi Y, Minegishi K, Nagasu K, Kanda H, Harada Y, Nagayama S, Katagiri T, Nakamura Y, Higashi T, Hasegawa S. alpha-particle therapy for synovial sarcoma in the mouse using an astatine-211-labeled antibpdy against fizzled homolog 10. Cancer Sci. 2018 Jul;109(7):2302-2309.
  6. 〇 Daizumoto K, Yoshimaru T, Matsushita Y, Fukawa T, Uehara H, Ono M, Komatsu M, Kanayama H, *Katagiri T. A DDX31/mutant-p53/EGFR axis promotes multistep progression of muscle invasive bladder cancer. Cancer Res., 2018 May 1;78(9):2233-2247.
  7. ○ Miyagawa Y#, Matsushita Y#, Suzuki H, Komatsu M, Yoshimaru T, Kimura R, Yanai A, Honda J, Tangoku A, Sasa M, Miyoshi Y, *Katagiri T. Frequent downregulation of LRRC26 by epigenetic alterations is involved in the malignant progression of triple-negative breast cancers. Int J Oncol. 2018 Mar 5. (# contributed equally)
  8. Sato S, Nakamura T, Katagiri T, Tsuchikawa T, Kushibiki T, Hontani K, Takahashi M, Inoko K, Takano H, Abe H, Takeuchi S, Ono M, Kuwabara S, Umemoto K, Suzuki T, Sato O, Nakamura Y, Hirano S. Molecular targeting of cell-permeable peptide inhibits pancreatic ductal adenocarcinoma cell proliferation. Oncotarget. 2017 Oct 19;8(69):113662-113672.
  9. Obara W, Kanehira M, Katagiri T, Kato R, Kato Y, Takata R. Present status and future perspective of peptide-based vaccine therapy for urological cancer. Cancer Sci. 2018, Mar; 109(3):550-559.

2017

  1. Nishimukai A, Inoue N, Kira A, Takeda M, Morimoto K, Araki K, Kitajima K, Watanabe T, Hirota S, Katagiri T, Nakamori S, Akazawa K, Miyoshi Y*. Tumor size and proliferative marker geminin rather than Ki67 expression levels significantly associated with maximum uptake of 18F-deoxyglucose levels on positron emission tomography for breast cancers. PLoS One. 2017 Sep 8;12(9):e0184508.
  2. Shigemizu D, Iwase T, Yoshimoto M, Suzuki Y, Miya F, Boroevich KA, Katagiri T, Zembutsu H*, Tsunoda T*. The prediction models for postoperative overall survival and disease-free survival in patients with breast cancer. Cancer Med. 2017 Jul;6(7):1627-1638
  3. 〇Yoshimaru T, Ono M, Bando Y, Chen YA, Mizuguchi K, Shima H, Komatsu M, Imoto I, Izumi K, Honda J, Miyoshi Y, Sasa M, Katagiri T*. A-kinase anchoring protein BIG3 coordinates oestrogen signaling in breast cancer cells. Nat Commun. 2017 May 30;8:15427. 【報道発表】乳がん細胞における新規エストロゲンシグナル制御機構の解明 〜新しいがん抑制因子の不活化機構の発見〜
  4. 〇Yoshimaru T*, Aihara K, Komatsu M, Matsushita Y, Okazaki Y, Toyokuni S, Honda J, Sasa M, Miyoshi Y, Otaka A, Katagiri T*. Stapled BIG3 helical peptide ERAP extends potent antitumor activity for breast cancer therapeutics. Sci Rep. 2017 May 12;7(1):1821 「報道発表」分子内架橋型ペプチドによるホルモン依存性乳がんの新規治療法の開発 〜臨床応用を見据えたペプチドの改良〜
  5. Iwamoto T*, Katagiri T, Niikura N, Miyoshi Y, Kochi M, Nogami T, Shien T, Motoki T, Taira N, Omori M, Tokuda Y, Fujiwara T, Doihara H, Gyorffy B, Matsuoka J. Immunohistochemical Ki67 after short-term hormone therapy identifies low-risk breast cancers as reliably as genomic markers. Oncotarget. 2017 Apr 18;8(16):26122-26128.
  6. Shikata Y, Yoshimaru T, Komatsu M, Katoh H, Sato R, Kanagaki S, Okazaki Y, Toyokuni S, Tashiro E, Ishikawa S, Katagiri T, Imoto M*. Protein kinase A inhibition facilitates the antitumor activity of xanthohumol, a valosin-containing protein inhibitor. Cancer Sci. 2017 Apr;108(4):785-794.
  7. ○Uno Y*, Takata R, Kito G, Yamazaki Y, Nakagawa K , Nakamura Y, Kamataki T, Katagiri T*. Sex- and age-dependent gene expression in human liver: an implication for drug-metabolizing enzymes. Drug Metabolism and Pharmacokinetics. 2017 Feb;32(1):100-107.
  8. Obara W*, Karashima T, Takeda K, Kato R, Kato Y, Kanehira M, Takata R, Inoue K, Katagiri T, Shuin T, Nakamura Y, Fujioka T. Effective induction of cytotoxic T cells recognizing an epitope peptide derived from Hypoxia-Inducible Protein 2 (HIG2) in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother. 2017 Jan;66(1):17-24..

2016

  1. ○Nakamura T, Katagiri T, Sato S, Kushibiki T, Tsuchikawa T, Hirano S, Nakamura Y. Overexpression of C16orf74 is involved in aggressive pancreatic cancers. Oncotarget. 2016 Jul 28. doi: 10.18632/oncotarget.10912.
  2. Park JH, Jang M, Tarhan YM, Katagiri T, Sasa M, Miyoshi Y, Kalari KR, Suman VJ, Weinshilboum R, Wang L, Boughey JC, Goetz MP, Nakamura Y. Clonal expansion of anti-tumor T cells in breast cancer correlates with response to neoadjuvant chemotherapy. Int J Oncol. 2016 Aug;49(2):471-8.

2015

  1. Imamura M, Nishimukai A, Higuchi T, Ozawa H, Yanai A, Miyagawa Y, Murase K, Sakita I, Hatada T, Takatsuka Y, Katagiri T, Miyoshi Y. High levels at baseline of serum pyridinoline crosslinked carboxyterminal telopeptide of type I collagen are associated with worse prognosis for breast cancer patients. Breast Cancer Res Treat. 2015 Dec;154(3):521-31.
  2. ○Kim NH,Yoshimaru T, Chen Y, Matsuo T, Komatsu M, Miyoshi Y, Tanaka E, Sasa M, Mizuguchi K, Katagiri T*. BIG3 inhibits the estrogen-dependent nuclear translocation of PHB2 via multiple Karyopherin-alpha proteins in breast cancer cells. PLoS One. 2015 Jun 8;10(6):e0127707.
  3. ○Yoshimaru T,Komatsu M, Miyoshi, Honda J, Sasa M, Katagiri T*. Therapeutic advances in BIG3-PHB2 inhibition targeting the crosstalk between estrogen and growth factors in breast cancer. Cancer Sci. 2015 May;106(5):550-8.
  4. ○Yanai A, Inoue N, Yagi T, Nishimukai A, Miyagawa Y, Murase K, Imamura M, Enomoto Y, Takatsuka Y, Watanabe T, Hirota S, Sasa M, Katagiri T, Miyoshi Y. Activation of mTOR/S6K But Not MAPK Pathways Might Be Associated With High Ki-67, ER+, and HER2- Breast Cancer. Clin Breast Cancer. 2015 Jun;15(3):197-203.
  5. Lo PH, Tanikawa C, Katagiri T, Nakamura Y, Matsuda K. Identification of novel epigenetically inactivated gene, PAMR1 in breast carcinoma. Oncol Rep. 2015 Jan;33(1):267-73.

2014

  1. ○Yoshimaru T, Komatsu M, Tashiro E, Imoto M, Osada H, Miyoshi Y, Honda J, Sasa M, Katagiri T*. Xanthohumol suppresses oestrogen-signalling in breast cancer through the specific inhibition of BIG3-PHB2 interactions. Sci Rep. 2014. Dec 8;4:7355.
  2. ○Matsuo T, Dat LT, Komatsu M, Yoshimaru T, Daizumoto K, Sone S, Nishioka Y, Katagiri T*. Early growth response 4 is involved in cell proliferation of small cell lung cancer through transcriptional activation of its downstream genes. PLoS One. 2014 Nov 20;9(11):e113606. PubMed
  3. ○Chen YA, Murakami Y, Ahmad S, Yoshimaru T, Katagri T, Mizuguchi K. Brefeldin a-inhibited guanine nucleotide-exchange protein 3 (BIG3) is predicted to interact with its partner through an ARM-type alpha-helical structure. BMC Res Notes. 2014 Jul 6;7(1):435.
  4. Yoshimura S, Tsunoda T, Osawa R, Harada M, Watanabe T, Hikichi T, Katsuda M, Miyazawa M, Tani M, Iwahashi M, Takeda K, Katagiri T, Nakamura Y, Yamaue H. Identification of an HLA-A2-restricted epitope peptide derived from hypoxia-inducible protein 2 (HIG2). PLoS One 2014 Jan 8;9(1):e85267.
  5. ○Matsuo T, Komatsu M, Yoshimaru T, Kiyotani K, Miyoshi Y, Sasa M, Katagiri T*. Involvement of B3GALNT2 overexpression in cell growth of breast cancer. Int J Oncol. 2014 Feb;44(2):427-34.

2013

  1. ○Low SK, Takahashi A, Ashikawa K, Inazawa J, Miki Y, Kubo M, Nakamura Y, Katagiri T. Genome-wide association study of breast cancer in the Japanese population. PLoS One. 2013 Oct 15;8(10):e76463.
  2. ○Yoshimaru T,Komatsu M, Matsuo T, Chen YA, Murakami,Y Mizuguchi K, Mizohata E, Inoue T, Akiyama M, Yamaguchi R, Imoto S, Miyano S, Miyoshi Y, Sasa M, Nakamura Y, Katagiri T*. Targeting BIG3-PHB2 interaction to overcome tamoxifen resistance in breast cancer cells. Nat. Communi. 2013;4:e2443.
  3. Yanai A, Miyagawa Y, Murase K, Imamura M, Yagi T, Ichii S, Takatsuka Y, Ito T, Hirota S, Sasa M, Katagiri T, Miyoshi Y. Influence of body mass index on clinicopathological factors including estrogen receptor, progesterone receptor, and Ki67 expression levels in breast cancers. Int J Clin Oncol. 2013 Jul 3.
  4. Kajita Y, Kato T Jr, Tamaki S, Furu M, Takahashi R, Nagayama S, Aoyama T, Nishiyama H, Nakamura E, Katagiri T, Nakamura Y, Ogawa O, Toguchida J. The transcription factor Sp3 regulates the expression of a metastasis-related marker of sarcoma, actin filament-associated protein 1-like 1 (AFAP1L1). PLoS One. 2013;8(1): e49709
  5. ○Komatsu M, Yoshimaru T, Matsuo T, Kiyotani, K, Miyoshi Y, Tanahashi T, Rokutan K, Yamaguchi R, Saito A, Miyano S, Nakamura Y, Sasa M, Shimada M, Katagiri T*. Molecular features of triple negative breast cancers by genome-wide gene expression profiling analysis. Int J Oncol. 2013 Feb;42(2):478-506

2012

  1. ○Fukawa T, Ono M, Matsuo T, Uehara H, Miki T, Nakamura Y, Kanayama H, Katagiri T*. DDX31 regulates the p53-HDM2 pathway and rRNA gene transcription through its interaction with NPM1 in renal cell carcinomas. Cancer Res. 2012 Nov 15;72(22):5867-77 [PubMed]
  2. Obara W, Ohsawa R, Kanehira M, Takata R, Tsunoda T, Yoshida K, Takeda K, Katagiri T, Nakamura Y, Fujioka T. Cancer Peptide Vaccine Therapy Developed from Oncoantigens Identified through Genome-wide Expression Profile Analysis for Bladder Cancer. Jpn J Clin Oncol. 2012 Jul;42(7):591-600.
  3. Murase K, Yanai A, Saito M, Imamura M, Miyagawa Y, Takatsuka Y, Inoue N, Ito T, Hirota S, Sasa M, Katagiri T, Fujimoto Y, Hatada T, Ichii S, Nishizaki T, Tomita N, Miyoshi Y. Biological characteristics of luminal subtypes in pre- and postmenopausal estrogen receptor-positive and HER2-negative breast cancers. Breast Cancer. 2012 Feb 23 (Epub) 2014.Jan21(1):52-7.
  4. Yoshioka H, Yamamoto S, Hanaoka H, Iida Y, Pramila P, Bishnuhari P, Higuchi T, Tominaga H, Oriuchi N, Nakagawa H, Shiba Y, Yoshida K, Osawa R, Katagiri T, Tsunoda T, Nakamura Y, Endo K. In vivo therapeutic effect of CDH3/P-Cadherin-targeting radioimmunotherapy. Cancer Immunol. Immunother. 2012; 61:1211-20.
  5. ○Dat LT, Matsuo T, Yoshimaru T, Kakiuchi S, Goto H, Hanibuchi M, Kuramoto T, Nishioka Y, Sone S, Katagiri T*. Identification of genes potentially involved in bone-metastasis by genome-wide gene-expression profiling analysis of non-small cell lung cancer in mice. Int J Oncol. 2012; 40:1455-69.[PubMed]

2011

  1. Furu M, Kajita Y, Nagayama S, Ishibe T, Shima Y, Uejima D, Aoyama T, Nakayama T, Nakamura T, Nakashima Y, Ikegawa M, Imoto S, Katagiri T, Nakamura Y, Toguchida J. Identification of AFAP1L1 as a prognostic marker for spindle cell sarcomas. Oncogene. 2011, in press [PubMed]
  2. Park J, Katagiri T, Chung S, Kijima K, Nakamura Y. Polypeptide N-acetylgalactosaminyltransferase 6 (GALNT6) disrupts mammary acinar morphogenesis through O-glycosylation of fibronectin. Neoplasia. 2011;13:320-6. [PubMed]

2010

  1. Ajiro M, Nishidate T, Katagiri T, Nakamura Y. Critical involvement of RQCD1 in the EGFR-Akt pathway in mammary carcinogenesis. Int J Oncol. 2010;37:1085-93. [PubMed]
  2. Kim JW, Fukukawa C, Nishidate T, Katagiri T, Nakamura Y. Involvement of C12orf32 overexpression in breast carcinogenesis. Int J Oncol. 2010;37:861-7. [PubMed]
  3. Harada Y, Kanehira M, Fujisawa Y, Takata R, Shuin T, Miki T, Fujioka T, Nakamura Y, Katagiri T. Cell-permeable peptide DEPDC1-ZNF224 interferes with transcriptional repression and oncogenicity in bladder cancer cells. Cancer Res. 2010;70:5829-39. [PubMed]
  4. Fukukawa C, Ueda K, Nishidate T, Katagiri T, Nakamura Y. Critical roles of LGN/GPSM2 phosphorylation by PBK/TOPK in cell division of breast cancer cells. Genes Chromosomes Cancer 2010;49:861-72. [PubMed]
  5. Park JH, Nishidate T, Kijima K, Ohashi T, Takegawa K, Fujikane T, Hirata K, Nakamura Y, Katagiri T. Critical roles of MUC1 glycosylation by transactivated GALNT6 (UDP-N-acetyl-D- galactosamine: polypeptide N-acetylgalactosaminyl transferase-6) in mammary carcinogenesis. Cancer Res. 2010;70:2759-69. [PubMed]
  6. Park JH, Nishidate T, Nakamura Y, Katagiri T. Critical roles of T-LAK cell-originated protein kinase in cytokinesis. Cancer Sci. 2010;101:403-11. [PubMed]

2009

  1. Ueki T, Park JH, Nishidate T, Kijima K, Hirata H, Nakamura Y, Katagiri T. Ubiquitination and downregulation of BRCA1 by UBE2T overexpression in human breast cancer cells. Cancer Res. 2009;69:8752-60. [PubMed]
  2. Ajiro M, Katagiri T, Ueda K, Nakagawa H, Fukukawa C, Lin ML, Park JH, Nishidate T, Daigo Y, Nakamura Y. Involvement of RQCD1 overexpression, a novel cancer-testis antigen, in the Akt pathway in breast cancer cells. Int J Oncol. 2009; 35:673-81. [PubMed]
  3. Kim JW, Akiyama M, Park JH, Lin ML, Shimo A, Ueki T, Daigo Y, Tatsuhiko T, Nishidate T, Nakamura Y, Katagiri T. Activation of an estrogen/ estrogen receptor signaling by BIG3 through its inhibitory effect on nuclear transport of PHB2/REA in breast cancer. Cancer Sci. 2009;100:1468-78. [PubMed]
  4. Lin ML, Fukukawa C, Park JH, Naito K, Kijima K, Shimo A, Ajiro M, Nishidate T, Nakamura Y, Katagiri T. Involvement of overexpression of G-patch domain containing 2 in breast carcinogenesis. Cancer Sci. 2009;100:1443-50. [PubMed]
  5. Morioka K, Tanikawa C, Ochi K, Daigo Y, Katagiri T, Kawano H, Kawaguchi H, Myoui A, Yoshikawa H, Naka N, Araki N, Kudawara I, Ieguchi M, Nakamura K, Nakamura Y, Matsuda K. Orphan receptor tyrosine kinase ROR2 as a potential therapeutic target for osteosarcoma. Cancer Sci. 2009;100:1227-33.
  6. Hanaoka H, Katagiri T, Fukukawa C, Yoshioka H, Yamamoto S, Iida Y, Higuchi T, Oriuchi N, Paudyal B, Paudyal P, Nakamura Y, Endo K. Radioimmunotherapy of solid tumors targeting a cell-surface protein, FZD10. Annuals of Nuclear Medicine, 2009;23:479-85.
  7. Ueda K, Fukase Y, Katagiri T, Ishikawa N, Irie S, Sato T, Ito H, Nakayama H, Miyagi Y, Tsuchiya E, Kohno N, Shiwa M, Nakamura Y, Daigo Y. Targeted serum glycoproteomics for the discovery of lung cancer-associated glycosylation disorders using lectin-coupled ProteinChip arrays. Proteomics 2009; 9:2182-92.
  8. Dobashi S, Katagiri T, Hirota E, Ashida S, Daigo Y, Shuin T, Fujioka T, Miki T, Nakamura Y. Involvement of TMEM22 overexpression in the growth of renal cell carcinoma cells. Oncol Rep. 2009;21:305-12. [PubMed]
  9. Fukukawa C, Nagayama S, Tsunoda T, Toguchida J, Nakamura Y, Katagiri T. Activation of non-canonical Dvl-Rac1-JNK pathway by Frizzled-homologue 10 (FZD10) in human synovial sarcoma. Oncogene. 2009; 28:1110-20. [PubMed]
  10. Nagayama S, Yamada E, Kohno Y Aoyama T., Fukukawa C, Kubo H, Watanabe G, Katagiri T, Nakamura, Y, Sakai Y, Toguchida J. Inverse correlation of the upregulation of FZD10 expression and the activation of beta-catenin in synchronous colorectal tumors. Cancer Sci. 2009;99: 2315-26.

2008

  1. Inoue H, Iga M, Nabeta H, Yokoo T, Suehiro Y, Okano S, Inoue M, Kinoh H, Katagiri T, Takayama K, Yonemitsu Y, Hasegawa M, Nakamura Y, Nakanishi Y, Tani K. Non-transmissible SeV encoding GM-CSF is a novel and potent vector system to produce autologous tumor vaccines. Cancer Sci. 2008;99:2315-26.
  2. Konda R, Sugimura J, Sohma F, Katagiri T, Nakamura Y, Fujioka T. Over Expression of Hypoxia-Inducible Protein 2, Hypoxia-Inducible Factor-1 alpha and Nuclear Factor kappaB is putatively involved in acquired renal cyst formation and subsequent tumor transformation in patients with end stage renal failure. J Urol. 2008;180:481-5.
  3. Ueki T, Nihidate T, Park JH, Lin ML, Shimo A, Hirata K, Nakamura Y, Katagiri T. Involvement of elevated expression of multiple cell-cycle regulator, DTL/RAMP (denticleless /RA-regulated nuclear matrix associated protein), in the growth of breast cancer cells. Oncogene. 2008;27:5672-83
  4. Fukukawa C, Hanaoka H, Nagayama S, Toguchida J, Endo K, Nakamura Y, Katagiri T. Radioimmunotherapy of human synovial sarcoma using a monoclonal antibody against FZD10. Cancer Sci. 2008; 99:432-40
  5. Kamatani Y, Matsuda K, Ohishi T, Ohtsubo S, Yamazaki K, Iida A, Hosono N, Kubo M, Yumura W, Nitta K, Katagiri T, Kawaguchi Y, Kamatani N, Nakamura Y. Identification of a significant association of a single nucleotide polymorphism in TNXB with systemic lupus erythematosus in a Japanese population. J Hum Genet. 2008;53:64-73.
  6. Shimo A, Tanikawa C, Lin ML, Nishidate T, Matsuda K, Ueki T, Park JH, Ohta T, Hirata K, Fukuda M, Nakamura Y, Katagiri T. Involvement of KIF2C/MCAK overexpression in mammary carcinogenesis. Cancer Sci. 2008;99:62-70.
  7. Kidokoro T, Tanikawa C, Furukawa Y, Katagiri T, Furukawa Y, Nakamura Y, Matsuda K. CDC20, a potential cancer therapeutic target, is negatively regulated by p53. Oncogene. 2008;27:1562-71.

2007

  1. Zembutsu H, Yanada M, Hishida A, Katagiri T, Tsuruo T, Sugiura I, Takeuchi J, Usui N, Naoe T, Nakamura Y, Ohno R. Prediction of risk of disease recurrence by genome-wide cDNA microarray analysis in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy. Int J Oncol. 2007;31:313-22.
  2. Senju S, Suemori H, Zembutsu H, Uemura Y, Hirata S, Fukuma D, Matsuyoshi H, Shimomura M, Haruta M, Fukushima S, Matsunaga Y, Katagiri T, Nakamura Y, Furuya M, Nakatsuji N, Nishimura Y. Genetically manipulated human embryonic stem cell-derived dendritic cells with immune regulatory function. Stem Cells. 2007;25:2720-9.
  3. Ueda K, Katagiri T, Shimada T, Irie S, Sato TA, Nakamura Y, Daigo Y. Comparative profiling of serum glycoproteome by sequential purification of glycoproteins and 2-nitrobenzensulfenyl (NBS) stable isotope labeling: a new approach for the novel biomarker discovery for cancer. J Proteome Res. 2007;6:3475-83.
  4. Fujikawa M, Katagiri T, Tugores A, Nakamura Y, Ishikawa F. ESE-3, an Ets family transcription factor, is up-regulated in cellular senescence. Cancer Sci. 2007;98:1468-75.
  5. Zembutsu H, Yanada M, Hishida A, Katagiri T, Tsuruo T, Sugiura I, Takeuchi J, Usui N, Naoe T, Nakamura Y, Ohno R. Prediction of risk of disease recurrence by genome-wide cDNA microarray analysis in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy. Int J Oncol. 2007;31:313-22.
  6. Kanehira M, Harada Y, Takata R, Shuin T, Miki T, Fujioka T, Nakamura Y, Katagiri T. Involvement of upregulation of DEPDC1 (DEP domain containing 1) in bladder carcinogenesis. Oncogene. 2007;26:6448-55.
  7. Kanehira M, Katagiri T, Shimo A, Takata R, Shuin T, Miki T, Fujioka T, Nakamura Y. Oncogenic role of MPHOSPH1, a cancer-testis antigen specific to human bladder cancer. Cancer Res. 2007;67:3276-85.
  8. Lin ML, Park JH, Nishidate T, Nakamura Y, Katagiri T. MELK, maternal embryonic leucine zipper kinase, involved in mammary carcinogenesis through interaction with Bcl-G, a pro-apoptotic member of Bcl-2 family. Breast Cancer Res. 2007;9:R17, 1-13.
  9. Shimo A, Nishidate T, Ohta T, Fukuda M, Nakamura Y, Katagiri T. Elevated expression of PRC1, protein regulator of cytokinesis 1, involved in the growth of breast cancer cells. Cancer Sci. 2007;98:174-81.

2006

  1. Takata R, Katagiri T, Kanehira M, Shuin T, Miki T, Namiki M, Kohri K, Tsunoda T, Fujioka T, Nakamura Y. Validation study of the prediction system for clinical response of M-VAC neoadjuvant chemotherapy. Cancer Sci. 2006;98:113-7.
  2. Park JH, Lin ML, Nishidate T, Nakamura Y, Katagiri T. PDZ-binding kinase/T-LAK cell-originated protein kinase, a putative cancer/testis antigen having an oncogenic activity in breast cancer. Cancer Res. 2006;66:9186-95.
  3. Iiizumi M, Hosokawa M, Takehara A, Chung S, Nakamura T, Katagiri T, Eguchi H, Ohigashi H, Ishikawa O, Nakamura Y, Nakagawa H. EphA4 receptor, overexpressed in pancreatic ductal adenocarcinoma, promotes cancer cell growth. Cancer Sci. 2006;97:1211-6.
  4. Takehara A, Eguchi H, Ohigashi H, Ishikawa O, Kasugai T, Hosokawa M, Katagiri T, Nakamura Y, Nakagawa H. Novel tumor marker REG4 detected in serum of patients with resectable pancreatic cancer and feasibility for antibody therapy targeting REG4. Cancer Sci. 2006;97:1191-7.
  5. Hirota E, Yan L, Tsunoda T, Ashida S, Fujime M, Shuin T, Miki T, Nakamura Y, Katagiri T. Genome-wide gene expression profiles of clear cell renal cell carcinoma; Identification of molecular targets for treatment of renal cell carcinoma. Int J Oncol. 2006;29:799-827.
  6. Ashida S, Furihata M, Katagiri T, Tamura K, Anazawa Y, Yoshioka M, Miki T, Fujioka T, Shuin T, Nakamura Y, Nakagawa H. Expression of novel molecules, MICAL2-PV (MICAL2 prostate cancer variants), increases with high Gleason score and prostate cancer progression. Clin Cancer Res. 2006;12:2767-73.
  7. Hamamoto R, Silva FP, Tsuge M, Nishidate T, Katagiri T, Nakamura, Furukawa Y. Enhanced SMYD3 expression is essential for the growth of breast cancer cells. Cancer Sci. 2006;97:113-8.
  8. Kikuchi T, Daigo Y, Ishikawa N, Katagiri T, Tsunoda T, Yoshida S, Nakamura Y. Expression profiles of metastatic brain tumor from lung adenocarcinomas on cDNA microarray. Int J Oncol. 2006;4:799-805.
  9. Morris JR, Pangon L, Boutell C, Katagiri T, Keep NH, Solomon E. Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibility. Hum Mol Genet. 2006;15:599-606.
  10. Tachiiri S, Katagiri T, Tsunoda T, Oya N, Hiraoka M, Nakamura Y. Analysis of gene-expression profiles after gamma irradiation of normal human fibroblasts. Int J Radiat Oncol Biol Phys. 2006;64:272-9.

2005

  1. Anazawa Y, Nakagawa H, Furihara M, Ashida S, Tamura K, Yoshioka H, Shuin T, Fujioka, Katagiri T, Nakamura Y. Analysis of gene-expression profiles after gamma irradiation of normal human fibroblasts. PCOTH, a novel gene overexpressed in prostate cancers, promotes prostate cancer cell growth through phosphorylation of oncoprotein TAF-Ibeta/SET. Cancer Res. 2005;65:4578-86.
  2. Obama K, Ura K, Li M, Katagiri T, Tsunoda T, Nomura A, Satoh S, Nakamura Y, Furukawa Y. Genome-wide analysis of gene expression in human intrahepatic cholangiocarcinoma. Hepatology. 2005;41:1339-48.
  3. Nagayama S, Fukukawa C, Katagiri T, Okamoto T, Aoyama T, Oyaizu N, Imamura M, Toguchida J, Nakamura Y. Therapeutic potential of antibodies against FZD10, a cell-surface protein, for synovial sarcomas. Oncogene. 2005;24:6201-12.
  4. Togashi A, Katagiri T, Ashida S, Fujioka T, Maruyama O, Wakumoto Y, Sakamoto Y, Fujime M, Kawachi Y, Shuin T, Nakamura Y. Hypoxia-inducible protein 2 (HIG2), a novel diagnostic marker for renal cell carcinoma (RCC) and potential target for molecular therapy. Cancer Res. 2005;65:4817-26.
  5. Takata R, Katagiri T, Kanehira M, Tsunoda T, Shuin T, Miki T, Namiki M, Kohri K, Matsushita Y, Fujioka T, Nakamura Y. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res. 2005;11:2625-36.
  6. Ishibe T, Nakayama T, Okamoto T, Aoyama T, Nishijo K, Shibata KR, Shima Y, Nagayama S, Katagiri T, Nakamura Y, Nakamura T, Toguchida J. Disruption of fibroblast growth factor signal pathway inhibits the growth of synovial sarcomas: potential application of signal inhibitors to molecular target therapy. Clin Cancer Res. 2005;11:2702-12.
  7. Taniuchi K, Nakagawa H, Hosokawa M, Nakamura T, Eguchi H, Ohigashi H, Ishikawa O, Katagiri T, Nakamura Y. Overexpressed P-cadherin/CDH3 promotes motility of pancreatic cancer cells by interacting with p120ctn and activating rho-family GTPases. Cancer Res. 2005;65:3092-9.
  8. Taniuchi K, Nakagawa H, Nakamura T, Eguchi H, Ohigashi H, Ishikawa O, Katagiri T, Nakamura Y. Down-regulation of RAB6KIFL/KIF20A, a kinesin involved with membrane trafficking of discs large homologue 5, can attenuate growth of pancreatic cancer cell. Cancer Res. 2005;65:105-12.

2004

  1. Nakatsura T, Komori H, Kubo, Y. Yoshitake, S. Senju, Katagiri T, Furukawa Y, Ogawa M, Nakamura Y, Nishimura Y. Mouse homologue of a novel human oncofetal antigen, glypican-3, evokes T-cell-mediated tumor rejection without autoimmune reactions in mice. Clin Cancer Res. 2004;10:8630-40.
  2. Kamiyama H, Kurosaki K, Kurimoto M, Katagiri T, Nakamura Y, Kurokawa M, Sato H, Endo S, Shiraki K. Herpes simplex virus-induced, death receptor-dependent apoptosis and regression of transplanted human cancers. Cancer Sci. 2004;95:990-8.
  3. Okada K, Hirota E, Mizutani Y, Fujioka T, Shuin T, Miki T, Nakamura Y, Katagiri T. Oncogenic role of NALP7 in testicular seminomas. Cancer Sci. 2004;95:949-54.
  4. Yoshitake Y, Nakatsura T, Monji M, Senju S, Matsuyoshi H, Tsukamoto H, Hosaka S, Komori H, Fukuma D, Ikuta Y, Katagiri T, Furukawa Y, Ito H, Shinohara M, Nakamura Y, Nishimura Y. Proliferation potential-related protein, an ideal esophageal cancer antigen for immunotherapy, identified using complementary DNA microarray analysis. Clin Cancer Res. 2004;10:6437-48.
  5. Nishidate T, Katagiri T, Lin ML, Mano Y, Miki Y, Kasumi F, Yoshimoto M, Tsunoda T, Hirata K, Nakamura Y. Genome-wide gene-expression profiles of breast-cancer cells purified with laser microbeam microdissection: identification of genes associated with progression and metastasis. Int J Oncol. 2004;25:797-819.
  6. Ashida S, Nakagawa H, Katagiri T, M. Furihata, M. Iiizumi, Y. Anazawa, Tsunoda T, R. Takata, K. Kasahara, T. Miki, T. Fujioka, T. Shuin, Nakamura Y. Molecular features of the transition from prostatic intraepithelial neoplasia (PIN) to prostate cancer: genome-wide gene-expression profiles of prostate cancers and PINs. Cancer Res. 2004;64:5963-72.
  7. Harima Y, Togashi A, Horikoshi K, Imamura M, Sougawa M, Sawada S, Tsunoda T, Nakamura Y, Katagiri T. Prediction of outcome of advanced cervical cancer to thermoradiotherapy according to expression profiles of 35 genes selected by cDNA microarray analysis. Int J Radiat Oncol Biol Phys. 2004;60:237-48.
  8. Nagayama S, Iiizumi M, Katagiri T, Toguchida J, Nakamura Y. Identification of PDZK4, a novel human gene with PDZ domains, that is up-regulated in synovial sarcomas. Oncogene. 2004;23:5551-7.
  9. Ochi K, Daigo Y, Katagiri T, Nagayama S, Tsunoda T, Myoui A, Naka N, Araki N, Kudawara I, Ieguchi M, Toyama Y, Toguchida J, Yoshikawa H, Nakamura Y. Prediction of response to neoadjuvant chemotherapy for osteosarcoma by gene-expression profiles. Int J Oncol. 2004;24:647-55.
  10. Nakamura T, Furukawa Y, Nakagawa H, Tsunoda T, Ohigashi H, Murata K, Ishikawa O, Ohgaki K, Kashimura N, Miyamoto M, Hirano S, Kondo S, Katoh H, Nakamura Y, Katagiri T. Genome-wide cDNA microarray analysis of gene-expression profiles in pancreatic cancers using populations of tumor cells and normal ductal epithelial cells selected for purity by laser microdissection. Oncogene. 2004;23:2385-400.
  11. Li M, Lin YM, Hasegawa S, Shimokawa T, Murata K, Kameyama M, Ishikawa O, Katagiri T, Tsunoda T, Nakamura Y, Furukawa Y. Genes associated with liver metastasis of colon cancer, identified by genome-wide cDNA microarray. Int J Oncol. 2004;24:305-12.

2003

  1. Okada K, Katagiri T, Tsunoda T, Mizutani Y, Suzuki Y, Kamada M, Fujioka T, Shuin T, Miki T, Nakamura Y. Analysis of gene-expression profiles in testicular seminomas using a genome-wide cDNA microarray. Int J Oncol. 2003;23:1615-35.
  2. Suzuki C, Daigo Y, Kikuchi T, Katagiri T, Nakamura Y. Identification of COX17 as a therapeutic target for non-small cell lung cancer. Cancer Res. 2003;63:7038-41.
  3. Kaneta Y, Kagami Y, Tsunoda T, Ohno R, Nakamura Y, Katagiri T. Genome-wide analysis of gene-expression profiles in chronic myeloid leukemia cells using a cDNA microarray. Int J Oncol. 2003;23:681-91.
  4. Zembutsu H, Ohnishi Y, Daigo Y, Katagiri T, Kikuchi T, Kakiuchi S, Nishime C, Hirata K, Nakamura Y. Gene-expression profiles of human tumor xenografts in nude mice treated orally with the EGFR tyrosine kinase inhibitor ZD1839. Int J Oncol. 2003;23:29-39.
  5. Nakatsura T, Yoshitake Y, Senju S, Monji M, Komori H, Motomura Y, Hosaka S, Beppu T, Ishiko T, Kamohara H, Ashihara H, Katagiri T, Furukawa Y, Fujiyama S, Ogawa M, Nakamura Y, Nishimura Y. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun. 2003;306:16-25.
  6. Ochi K, Daigo Y, Katagiri T, Saito-Hisaminato A, Tsunoda T, Toyama Y, Matsumoto H, Nakamura Y. Expression profiles of two types of human knee-joint cartilage. J Hum Genet. 2003;48:177-82.
  7. Kikuchi T, Daigo Y, Katagiri T, Tsunoda T, Okada K, Kakiuchi S, Zembutsu H, Furukawa Y, Kawamura M, Kobayashi K, Imai K, Nakamura Y. Expression profiles of non-small cell lung cancers on cDNA microarrays: identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs. Oncogene. 2003;22:2192-205.
  8. Arimoto T, Katagiri T, Oda K, Tsunoda T, Yasugi T, Osuga Y, Yoshikawa H, Nishii O, Yano T, Taketani Y, Nakamura Y. Genome-wide cDNA microarray analysis of gene-expression profiles involved in ovarian endometriosis. Int J Oncol. 22:551-60.
  9. Abe S, Katagiri T, Saito-Hisaminato A, Usami S, Inoue Y, Tsunoda T, Nakamura Y. Identification of CRYM as a candidate responsible for nonsyndromic deafness, through cDNA microarray analysis of human cochlear and vestibular tissues. Identification of CRYM as a candidate responsible for nonsyndromic deafness, through cDNA microarray analysis of human cochlear and vestibular tissues. Am J Hum Genet. 2003;72:73-82.

2002

  1. Okutsu J, Tsunoda T, Kaneta Y, Katagiri T, Kitahara O, Zembutsu H, Yanagawa R, Miyawaki S, Kuriyama K, Kubota N, Kimura Y, Kubo K, Yagasaki F, Higa T, Taguchi H, Tobita T, Akiyama H, Takeshita A, Wang Y, Motoji T, Ohno R, Nakamura Y. Prediction of chemosensitivity for patients with acute myeloid leukemia, according to expression levels of 28 genes selected by genome-wide complementary DNA microarray analysis. Mol Cancer Ther. 2002;1:1035-42.
  2. Hasegawa S, Furukawa Y, Li M, Satoh S, Kato T, Watanabe T, Katagiri T, Tsunoda T, Yamaoka Y, Nakamura Y. Genome-wide analysis of gene expression in intestinal-type gastric cancers using a complementary DNA microarray representing 23,040 genes. Cancer Res. 2002;62:7012-7.
  3. Nagamaya S, Katagiri T, Tsunoda T, Hosaka T, Nakashima Y, Araki N, Kusuzaki K, Nakayama T, Tsuboyama T, Nakamura T, Imamura M, Nakamura Y, Toguchida J. Genome-wide analysis of gene expression in synovial sarcomas using a cDNA microarray. Cancer Res. 62:5859-66.
  4. Brown M, Nicolai H, Howe K, Katagiri T, Lalani E, Simpson K, Manning N, Deans A, Chen P, Khanna KK, Wati MR, Griffiths B, Xu C, Stamp G, Solomon E. Expression of a truncated Brca1 protein delays lactational mammary development in transgenic mice. Transgenic Res. 2002;11:467-78.
  5. Kaneta Y, Kagami Y, Katagiri T, Tsunoda T, Jin-nai I, Taguchi H, Hirai H, Ohnishi K, Ueda T, Emi N, Tomida A, Tsuruo T, Nakamura Y, Ohno R. Prediction of sensitivity to STI571 among chronic myeroid leukemia patients by genome-wide cDNA microarray analysis. Jpn J Cancer Res. 2002;93:849-56.
  6. Kitahara O, Katagiri T, Tsunoda T, Harima Y, Nakamura Y. Classification of sensitivity or resistance of cervical cancers to ionizing radiation according to expression profiles of 62 genes selected by cDNA microarray analysis. Neoplasia. 2002;4:295-303.
  7. Saito-Hisaminato A*, Katagiri T*, Kakiuchi S, Nakamura T, Tsunoda T, Nakamura Y. Genome-wide profiling of gene expression in 29 normal human tissues with a cDNA microarray. DNA Res. 2002;9:35-45. (*equal contributors)
  8. Miura K, Bowman ED, Simon R, Peng AC, Robles AI, Jones RT, Katagiri T, He P, Mizukami H, Charboneau L, Kikuchi T, Liotta LA, Nakamura Y, Harris CC. Laser capture microdissection and microarray expression analysis of lung adenocarcinoma reveals tobacco smoking and prognosis-related molecular profiles. Cancer Res. 2002;62:3244-50.
  9. Dan S, Tsunoda T, Kitahara O, Yanagawa R, Zembutsu H, Katagiri T, Yamazaki K, Nakamura Y, Yamori T. An integrated database of chemosensitivity to 55 anticancer drugs. Cancer Res. 2002;62:1139-47.
  10. Zembutsu H, Ohnishi Y, Tsunoda T, Furukawa Y, Katagiri T, Ueyama Y, Tamaoki N, Nomura T, Kitahara O, Yanagawa R, Hirata K, Nakamura Y. Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs. Cancer Res. 2002;62:518-27.

2001

  1. Maeda K, Matsuhashi S, Tabuchi K, Watanabe T, Katagiri T, Oyasu M, Saito N, Kuroda S. Brain specific human genes, NELL1 and NELL2, are predominantly expressed in neuroblastoma and other embryonal neuroepithelial tumors. Neurol Med Chir. 2001;41:582-8.

2000

  1. Kato M, Yano K, Matsuo F, Saito H, Katagiri T, Kurumizaka H, Yoshimoto M, Kasumi F, Akiyama F, Sakamoto G, Nagawa H, Nakamura Y, Miki Y. Identification of Rad51 alteration in patients with bilateral breast cancer. J Human Genet. 2000;45:133-7.
  2. Futamura M, Arakawa H, Matsuda K, Katagiri T, Saji S, Miki Y, Nakamura Y. Potential role of BRCA2 in a mitotic checkpoint after phosphorylation by hBUBR1. Cancer Res. 2000;60:1531-5.

1999

  1. Emi M, Yoshimoto M, Sato T, Matsumoto S, Y. Utada, I. Ito, K. Minobe, T. Iwase, Katagiri T, Bando K, Akiyama F, Harada Y, Fukino K, Sakamoto G, Matsushima M, Iida A, Tada T, Saito H, Miki Y, Kasumi F, Nakamura Y. Allelic loss at 1p34, 13q12, 17p13.3, and 17q21.1 correlates with poor postoperative prognosis in breast cancer. Genes Chromosomes Cancer. 1999;26:134-41.
  2. Katagiri T, Futamura M, Nakamura Y. A Gln/Arg polymorphism at codon 349 of the hBUBR1 gene. J Human Genet. 1999;44:131-2.

1998

  1. Maruyama O, Nishimori H, Katagiri T, Miki Y, Ueno A, Nakamura Y. Cloning of TCFL5 encoding a novel human basic helix-loop-helix motif protein that is specifically expressed in primary spermatocytes at the pachytene stage. Cytogenet Cell Genet. 1998;82:41-5.
  2. Katagiri T, Saito H, Shinohara A, Ogawa H, Kamada N, Nakamura Y, Miki Y. Multiple possible sites of BRCA2 interacting with DNA repair protein Rad51. Genes Chromosomes Cancer. 1998;21:217-22.
  3. Katagiri T, Kasumi F, Yoshimoto M, Asaishi K, Abe R, Tsuchiya A, Sugano M, Nomizu T, Takai S, Yoneda M, Nanba K, Makita M, Okazaki H, Hirata K, Okazaki M, Furutsuma Y, Morishita Y, Iino Y, Karino T, Fukutomi T, Ayabe H, Hara S, Kajiwara T, Houga S, Shimizu T, Toda M, Yamasaki Y, Uchida T, Kunitomo K, Sonoo H, Kurebayashi J, Shimotuma K, Nakamura Y, Miki Y. High proportion of missense mutations of the BRCA1 and BRCA2 genes in Japanese breast cancer families. J Human Genet. 1998;43:42-8.
  4. Emi M, Matsushima M, Katagiri T, Yokota T, Nakata T, Kasumi F, Miki Y, Skolnick MH, Nakamura Y. Multiplex mutation screening of the BRCA1 gene in 1000 Japanese breast cancers: 2-3% of Japanese breast cancer is attributable to BRCA1 mutations. Jpn J Cancer Res.1998;89:12-4.

1997

  1. Miki Y, Katagiri T, Nakamura Y. Infrequent mutation of the H-Cadherin gene on chromosome 16q24 in human breast cancers. Jpn J Cancer Res. 1997;88:701-4.
  2. Shimizu F, Katagiri T, Suzuki M, Watanabe TK, Okuno S, Kuga Y, Nagata M, Fujiwara T, Nakamura Y, Takahashi E. Cloning and chromosome assignment to 1q32 of a human cDNA (RAB7L1) encoding a small GTP-binding protein, a member of the RAS superfamily. Cytogenet Cell Genet. 1997;77:261-3.
  3. Takeda S, Fujiwara T, Shimizu F, Kawai A, Shinomiya K, Okuno S, Ozaki K, Katagiri T, Shimada Y, Nagata M, Watanabe T, Takaichi A, Kuga Y, Suzuki M, Hishigaki H, Takahashi E, Shin S, Nakamura Y, Hirai Y. Isolation and mapping of karyopherin alpha 3 (KPNA3), a human gene that is highly homologous to genes encoding Xenopus importin, yeast SRP1 and human RCH1. Cytogenet Cell Genet. 1997;76:87-93.

1996

  1. Watanabe TK*, Katagiri T*, Suzuki M, Shimizu F, Fujiwara T, Kanemoto N, Nakamura Y, Hirai Y, Maekawa H, Takahashi E. Cloning and characterization of two novel human cDNAs (NELL1 and NELL2) encoding proteins with six EGF-like repeats. Genomics. 1996;38:273-6. (*equal contributors)
  2. Katagiri T, Ozaki K, Fujiwara T, Shimizu F, Kawai A, Okuno S, Suzuki M, Nakamura Y, Takahashi E, Hirai Y. Cloning, expression, and chromosome mapping of adducin-(alpha) like 1 (ADDL1), a human cDNA highly homologous to human erythrocyte adducin. Cytogenet Cell Genet. 1996;74:90-5.
  3. Katagiri T, Nakamura Y, Miki Y. Mutations in the BRCA2 gene in hepatocellular carcinomas. Cancer Res. 1996;56:4575-7.
  4. Miki Y, Katagiri T, Kasumi F, Yoshimoto T, Nakamura Y. Mutation analysis in the BRCA2 gene in primary breast cancers. Nature Genet. 1996;13: 245-7.
  5. Katagiri T, Emi M, Ito I, Kobayashi K, Yoshimoto M, Watanabe S, Iwase T, Kasumi F, Miki Y, Skolnick MH, Nakamura Y. Mutations in the BRCA1 gene in Japanese breast cancer patients. Human Mutat. 1996;7:334-9.

1995

  1. Ito I, Yoshimoto M, Iwase T, Watanabe S, Katagiri T, Harada Y, Kasumi F, Yasuda S, Mitomi T, Emi M, Nakamura Y. Association of genetic alterations on chromosome 17 and loss of hormone receptors in breast cancer. Br J Cancer. 1995;71:438-41.
  2. Katagiri T, Harada Y, Emi M, Nakamura Y. Human metalloprotease/ disintegrin-like (MDC) gene: exon-intron organization and alternative splicing. Cytogenet Cell Genetics. 1995;68:39-44.

1994

  1. Harada Y, Katagiri T, Ito I, Akiyama F, Sakamoto G, Kasumi F, Nakamura Y, Emi M. Genetic studies of 457 breast cancers. Clinicopathologic parameters compared with genetic alterations. Cancer. 1994;74:2281-6.
  2. Isomura M, Tanigami A, Saito H, Harada Y, Katagiri T, Inazawa J, Ledbetter DH, Nakamura Y. Detailed analysis of heterozygosity on chromosome band 17p13 in breast carcinoma on the basis of a high-resolution physical map with 29 markers. Genes Chromosomes Cancer. 1994;9:173-9.

1993

  1. Emi M, Katagiri T, Harada Y, Saito H, Inazawa J, Ito I, Kasumi F, Nakamura Y. A novel metalloprotease/ disintegrin-like gene at 17q21.3 is somatically rearranged in two primary breast cancers. Nature Genet. 1993;5: 151-7.
  2. Ichii M, Katagiri T, Hasegawa H, Yatou O, Kirk DW, Wray JL. Biochemical characterization of rice (Oryza sativa L.) mutants defective or low in nitrate reduction. Tech Bull Fac Agric Kagawa University. 1995;47:1-6.
  3. Ichii M, Katagiri T, Hasegawa H. Mutants with low nitrate reductase activity selected from seedlings expressing nitrogen deficiency symptoms in rice (Oryza sativa L.). Jpn J Breed. 1993;43:123-7.

1992

  1. Hasegawa H, Katagiri T, Ida S, Yatou O, Ichii M. Characterization of a rice (Oryza sativa L.) mutant deficient in the heme domain of nitrate reductase. Theor Appl Genet. 1992;84:6-9.

1991

  1. Hasegawa H, Yatou O, Katagiri T, Ichii M. Screening for nitrate reductase deficient mutants in rice (Oryza sativa L.). Jpn J Breed. 1991;41:95-101.

Review Article

  1. Fukukawa C, Nakamura Y, Katagiri T. Molecular target therapy for synovial sarcoma. Future Oncology. 2005;1:805-12.

トップページ「新着情報」欄に表示する画像

研究成果 ／ イベント ／ 公募 ／ お知らせ のいずれかを入力してください。

お知らせ